Physician profile
Emily R Roach
NPI 1811579287
$923.13
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $319 · 2022: $366 · 2023: $106 · 2024: $131.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $238.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $237.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $185.78 | 2021-2024 | Mounjaro |
| Janssen Pharmaceuticals, INC | $167.40 | 2021-2022 | |
| Astrazeneca Pharmaceuticals Lp | $115.76 | 2021-2024 | Airsupra, Farxiga, Breztri |
| Bayer Healthcare Pharmaceuticals INC. | $79.77 | 2021-2023 | |
| Abbvie INC. | $58.99 | 2022-2023 | |
| Upsher-Smith Laboratories LLC | $50.82 | 2021-2022 | |
| Amgen INC. | $46.80 | 2024 | Repatha |
| Novo Nordisk INC | $44.82 | 2022-2024 | Rybelsus, Ozempic |
| Glaxosmithkline, LLC. | $35.67 | 2021-2022 | |
| Dexcom, INC. | $32.64 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $28.34 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $25.64 | 2021 | |
| Eisai INC. | $21.39 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $16.07 | 2022 | |
| Abiomed | $13.24 | 2024 | Impella |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emily Roach listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.